SCHEMBL4093470

SCHEMBL4093470

CC(C)(C)CNS(=O)(=O)c1ccccc1Nc1nc(Cl)ncc1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 6/20 0.50
MAPK8 P45983 2/20 0.48
CDK7 P50613 10/20 0.46
CDK9 P50750 10/20 0.46
INSR P06213 3/20 0.46
IGF1R P08069 2/20 0.46
PTK2 Q05397 2/20 0.46
CDC7 O00311 1/20 0.46
PLK4 O00444 1/20 0.46
CHEK1 O14757 1/20 0.46
AURKA O14965 1/20 0.46
DCLK1 O15075 1/20 0.46
MAPK13 O15264 1/20 0.46
PDPK1 O15530 1/20 0.46
DYRK3 O43781 1/20 0.46
JAK2 O60674 1/20 0.46
ROCK2 O75116 1/20 0.46
RPS6KA5 O75582 1/20 0.46
PRKD3 O94806 1/20 0.46
MAP4K4 O95819 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4099901 0.85 ALK (0.49) ALKMAPK8CDK7CDK9INSR
SCHEMBL375003 0.84 CDK7 (0.61) ALKMAPK8CDK7CDK9INSR
SCHEMBL29904751 0.84 CDK7 (0.61) ALKMAPK8CDK7CDK9INSR
SCHEMBL375715 0.82 ALK (0.55) ALKMAPK8CDK7CDK9INSR
SCHEMBL2061222 0.81 ALK (0.71) ALKMAPK8CDK7CDK9INSR
SCHEMBL31512671 0.81 ALK (0.71) ALKMAPK8CDK7CDK9INSR
SCHEMBL375081 0.81 ALK (0.52) ALKMAPK8CDK7CDK9INSR
SCHEMBL375482 0.81 ALK (0.49) ALKMAPK8CDK7CDK9INSR
SCHEMBL19557714 0.80 ALK (0.53) ALKMAPK8CDK7CDK9INSR
SCHEMBL375487 0.80 ALK (0.48) ALKMAPK8CDK7CDK9INSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090131436-A1 Pyrimidine Derivatives NOVARTIS AG (CH) 2009-05-21 US disclosed
US-20090131436-A1 Pyrimidine Derivatives NOVARTIS AG (CH) 2009-05-21 US disclosed
US-20090131436-A1 Pyrimidine Derivatives NOVARTIS AG (CH) 2009-05-21 US disclosed
EP-1784392-A2 PYRIMIDINE DERIVATIVES Novartis AG (CH) 2007-05-16 EP disclosed
WO-2006021454-A2 PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131436-A1 Pyrimidine Derivatives DPYD, TYMP, TYMS ALK 2060/4885MAPK8 3075/4885CDK7 167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.